RALYL Inhibitors
RNA-binding proteins play pivotal roles in a variety of cellular processes, and their dysregulation can be implicated in various cellular malfunctions. Inhibitors targeting specific RNA-binding proteins aim to modulate their activity, thereby influencing the processes they regulate. RALYL Inhibitors, would specifically target the RALYL RNA-binding protein, modulating its interaction with RNA molecules.
The design and development of such inhibitors would likely involve understanding the structural and functional characteristics of RALYL. By identifying the specific domains of RALYL that interact with RNA, potential compounds could be designed to bind these regions, preventing the protein from effectively binding RNA. Various methods, including computational modeling, molecular docking, and in vitro binding assays, could be employed to identify and validate potential inhibitor compounds. Moreover, understanding the downstream effects of RALYL inhibition at the cellular level would be crucial. By doing so, researchers could gain insights into how modulation of RALYL's activity impacts cellular processes, RNA metabolism, and overall cell health. The development and study of RALYL Inhibitors would enrich our understanding of RNA-protein interactions and provide tools for further research in cellular biology.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $73.00 $238.00 $717.00 $2522.00 $21420.00 | 53 | |
Actinomycin D binds to DNA, preventing RNA polymerase from attaching and transcribing genes, which can inhibit the transcription of the RALYL gene. | ||||||
Mycophenolic acid | 24280-93-1 | sc-200110 sc-200110A | 100 mg 500 mg | $68.00 $261.00 | 8 | |
Mycophenolic acid inhibits inosine monophosphate dehydrogenase, leading to a decrease in guanosine synthesis, which can affect RNA synthesis and potentially the expression of RALYL. | ||||||
Fluorouracil | 51-21-8 | sc-29060 sc-29060A | 1 g 5 g | $36.00 $149.00 | 11 | |
5-Fluorouracil is a thymidylate synthase inhibitor, which can disrupt DNA synthesis and RNA transcription processes, potentially affecting RALYL gene expression. | ||||||
α-Amanitin | 23109-05-9 | sc-202440 sc-202440A | 1 mg 5 mg | $260.00 $1029.00 | 26 | |
α-Amanitin inhibits RNA polymerase II, thereby preventing mRNA synthesis, which can affect the transcription of the RALYL gene. | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $97.00 $254.00 | 36 | |
Anisomycin inhibits protein synthesis by binding to the ribosome, which could prevent RALYL mRNA from being translated. | ||||||
DRB | 53-85-0 | sc-200581 sc-200581A sc-200581B sc-200581C | 10 mg 50 mg 100 mg 250 mg | $42.00 $185.00 $310.00 $650.00 | 6 | |
DRB inhibits the activity of RNA polymerase II, potentially preventing the transcription of the RALYL gene. | ||||||
Puromycin dihydrochloride | 58-58-2 | sc-108071 sc-108071B sc-108071C sc-108071A | 25 mg 250 mg 1 g 50 mg | $40.00 $210.00 $816.00 $65.00 | 394 | |
Puromycin causes premature chain termination during translation, which could prevent the RALYL protein from being fully synthesized. | ||||||
Cordycepin | 73-03-0 | sc-203902 | 10 mg | $99.00 | 5 | |
Cordycepin is an adenosine analogue, which can be incorporated into RNA and cause premature termination, potentially affecting RALYL mRNA stability and translation. | ||||||
Ribavirin | 36791-04-5 | sc-203238 sc-203238A sc-203238B | 10 mg 100 mg 5 g | $62.00 $108.00 $210.00 | 1 | |
Ribavirin is a guanosine analogue that can affect RNA synthesis, potentially influencing the expression of RALYL. | ||||||
Trifluorothymidine | 70-00-8 | sc-222370 sc-222370A | 100 mg 1 g | $179.00 $500.00 | 1 | |
Trifluridine is a thymidine analogue that can be incorporated into DNA, potentially affecting the transcription and replication of genes, including RALYL. | ||||||